Interaction of valerian extracts of different polarity with adenosine receptors: Identification of isovaltrate as an inverse agonist at A1 receptors

Biochemical Pharmacology

Volumn 73, Issue 2, 2007, Pages 248-258

  Lacher, Svenja K ^a   Mayer, Ralf ^a   Sichardt, Kathrin ^b   Nieber, Karen ^b   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

A1 antagonist; Adenosine receptors; Bioassay guided fractionation; Inverse agonist; Isovaltrate; Valerian

Indexed keywords

6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ETHER; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ISOVALTRATE; PETROLEUM ETHER; RADIOLIGAND; VALERIAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN CELL; BRAIN SLICE; CHO CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HYDROPHILICITY; ISOLATION PROCEDURE; LIPOPHILICITY; MALE; NONHUMAN; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; RAT; RECEPTOR UPREGULATION; VALERIANA OFFICINALIS;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ELECTRIC STIMULATION; LIGANDS; PLANT EXTRACTS; RECEPTORS, PURINERGIC P1; SPECTROPHOTOMETRY, INFRARED; VALERIAN;

EID: 33845207239     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.09.029     Document Type: Article

References (34)

1. Houghton P.J. The scientific basis for the reputated activity of valerian. J Pharm Pharmacol 51 (1999) 505-512
2. Ziegler G., Ploch M., Miettinen-Baumann A., and Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia-a randomized, double-blind, comparative clinical study. Eur J Med Res 7 (2002) 480-486
3. Wagner J., Wagner M.L., and Hening W.A. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 32 (1998) 680-691
4. Trevana L. Practice corner: sleepless in Sydney-is valerian an effective alternative to benzodiazepines in the treatment of insomnia?. ACP J Club 141 (2004) A14-A16
5. Malva J.O., Santos S., and Macedo T. Neuroprotective properties of Valeriana officinalis extracts. Neurotox Res 6 (2004) 131-140
6. 6-cyclohexyladenosine binding to rat cortical membranes by an hydro-alcoholic extract of Valeriana officinalis. Med Sci Res 17 (1998) 639-640
7. Müller C.E., Schumacher B., Brattström A., Abourashed E.A., and Kötter U. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci 71 (2002) 1939-1949
8. 1 receptors in rat cortical neurons. Planta Med 72 (2006) 579-583
9. Schellenberg R., Sauer S., Abourashed E.A., Kötter U., and Brattström A. The fixed combination of valerian and hops (Ze 91019) acts via a central adenosine mechanism. Planta Med 70 (2004) 594-597
10. 1 adenosine receptors. J Nat Prod 65 (2002) 1479-1485
11. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.-N., and Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53 (2001) 527-552
12. Basheer R., Strecker R.E., Thakkar M.M., and McCarley R.W. Adenosine and sleep-wake regulation. Prog Neurobiol 73 (2004) 379-396
13. 1 receptor mediate inhibition of cAMP formation in vitro in the pontine, REM sleep induction zone. Brain Res 1061 (2005) 124-127
14. 1 receptor-dependent G-protein activity in the rat brain during prolonged wakefulness. Neuroreport 15 (2004) 2133-2137
15. 1 receptors mediate the arousal effect of caffeine. Nat Neurosci 8 (2005) 858-859
16. Yan L., Burbiel J.C., Maaß A., and Müller C.E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8 (2003) 537-576
17. 1 adenosine receptor antagonists. Exp Opin Ther Patents 1997; 7:419-40.
18. 2A receptor as an attractive target for Parkinson's disease treatment. Drug News Perspect 16 (2003) 597-604
19. Bigler P. Modern homo- and heteronuclear 1D and 2D NMR experiments: a short overview. NMR spectroscopy: processing strategies (2000), Wiley-VCH, Weinheim, Germany p. 60-77
20. Thies P.W., Finner E., and David S. Über die Wirkstoffe des Baldrians - XIV. Konstitutive Zuordnung der Acyloxysubstituenten in Valepotriaten via C13-NMR-Spektroskopie (On the bioactive agents of valerian - XIV. Assignment of type and location of the acyloxy substituents in valepotriates via C13-NMR spectroscopy). Planta Med 41 (1981) 15-20
21. Bos R., Woerdenbag H.J., and Pras N. Determination of valepotriates. J Chromatogr A 967 (2002) 131-146
22. Thies P.W., Finner E., and Rosskopf F. Über die Wirkstoffe des Baldrians - X. Die Konfiguration des Valtratum und anderer Valepotriate. (The configuration of valtratum and other valepotriates). Tetrahedron 29 (1973) 3213-3226
23. Handjieva N.V., Mollova N.N., and Popov S.S. Chemical ionisation mass spectrometry of valepotriates using isobutane as reactant gas. Planta Med 53 (1987) 198-201
24. 3H]NECA in rat striatal membranes. Mol Pharmacol 29 (1986) 331-346
25. Lohse M.J., Lenschow V., and Schwabe U. Interaction of barbiturates with adenosine receptors in rat brain. Nauyn Schmiedeberg's Arch Pharmacol 326 (1984) 69-74
26. 1 adenosine receptors. Nauyn Schmiedeberg's Arch Pharmacol 340 (1989) 679-683
27. 3H]MSX-2(3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes. Eur J Pharm Sci 10 (2000) 259-265
28. 1 adenosine receptor with receptor/G-protein complexes in rat brain membranes. Mol Pharmacol 49 (1996) 915-926
29. Klotz K.-N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B., et al. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Nauyn Schmiedeberg's Arch Pharmacol 357 (1998) 1-9
30. 3 receptors mediate inhibition of synaptic transmission in rat cortical neurons. Neuropharmacology 40 (2001) 85-95
31. 3 receptors by endogenous adenosine inhibits synaptic transmission during hypoxia in rat cortical neurons. Restor Neurol Neurosci 21 (2003) 55-63
32. 1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. Chem Med Chem 1 (2006) 891-902
33. Thies P.W. Zur Chemie der Valepotriate. 4. Mitteilung über die Wirkstoffe des Baldrians (on the chemistry of valepotriates. 4. Report on the bioactive constituents of valerian). Deutsche Apotheker Zeitung 107 (1967) 1411-1412
34. Daly J.W., Hide I., Müller C.E., and Shamim M. Caffeine analogs: structure-activity relationships at adenosine receptors. Pharmacology 42 (1991) 309-321